Benralizumab

Uses

How it works

Benefits

Dosage & preparation

Interactions

Comparisons

Background

Evidence quality

Highlighted claims

• Benralizumab was evaluated against placebo in a randomized, placebo-controlled phase 3 trial as a treatment for hypereosinophilic syndrome. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
• The baseline median eosinophil count in the benralizumab treatment group (n=67) was corrected to 1,085.0 cells with a range of 360–5,620. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
• The corrected baseline median eosinophil count in benralizumab-treated patients is 1,085.0 cells with a range of 360–5,620. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
• Corrected baseline median eosinophil count for the benralizumab group is 1,085.0 cells with a range of 360–5,620. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
• Benralizumab was evaluated against placebo in a randomized phase 3 trial for hypereosinophilic syndrome. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
• A subset of 67 patients received both omalizumab and benralizumab. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
• Benralizumab was evaluated against placebo for treating hypereosinophilic syndrome in a randomized, placebo-controlled phase 3 trial. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
• The benralizumab treatment group in the trial comprised 67 patients with a corrected baseline median eosinophil count of 1,085.0 cells. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
• The benralizumab treatment arm in the trial comprised 67 patients. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
• The baseline median eosinophil count for patients assigned to benralizumab was corrected from 1,070.0 to 1,085.0 cells, with the lower range boundary raised from 230 to 360. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems